Persintia (pertuzumab biosimilar)
/ R-Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 02, 2026
R-Pharm has received marketing authorization from the Russian Ministry of Health for Persintia, a biosimilar of the cancer drug pertuzumab.
(GxP News)
- "In a Phase III clinical trial involving approximately 250 patients, the biosimilar demonstrated non-inferior efficacy and a comparable safety profile to the originator drug, the company emphasized."
Approval • HER2 Positive Breast Cancer
1 to 1
Of
1
Go to page
1